Cagrilintide vs Semaglutide
Cagrilintide and semaglutide act on entirely different appetite-regulation systems. Cagrilintide is a long-acting amylin analog, while semaglutide is a GLP-1 receptor agonist. The two are frequently studied together because their mechanisms are complementary.
Side-by-Side Comparison
| Property | Cagrilintide | Semaglutide |
|---|---|---|
| Category | Long-acting amylin analog (dual amylin/calcitonin receptor agonist) | GLP-1 receptor agonist |
| Mechanism of Action | Activates amylin and calcitonin receptors; promotes meal-ending satiation via the area postrema and hindbrain circuits, slows gastric emptying | Activates GLP-1 receptor; stimulates insulin secretion, suppresses glucagon, reduces appetite via hypothalamic and hindbrain pathways |
| Molecular Weight | ~4,409 Da (lipidated amylin analog) | ~4,113 Da |
| Primary Research Focus | Body weight regulation, satiation signaling, combination protocols with GLP-1 agonists | Type 2 diabetes, obesity, cardiovascular risk reduction |
| Receptor Target | Amylin receptors (AMY1-3) + calcitonin receptor | GLP-1 receptor (selective) |
| Half-Life | ~7-8 days (lipidation enables albumin binding) | ~7 days (C-18 fatty diacid, albumin binding) |
| Key Research Citations | Lau et al. (2021), Lancet phase 2; Enebo et al. (2021), Lancet (cagrilintide + semaglutide 2.4 mg phase 1b) | Wilding et al. (2021), STEP-1, NEJM; Marso et al. (2016), SUSTAIN-6, NEJM |
Key Differences
- Cagrilintide mimics amylin, a pancreatic beta-cell hormone co-secreted with insulin; semaglutide mimics GLP-1, an intestinal incretin hormone. They engage separate receptor families.
- Cagrilintide acts predominantly on hindbrain satiation circuits (area postrema); semaglutide combines appetite effects with direct incretin actions on insulin and glucagon secretion.
- Semaglutide has completed phase 3 and cardiovascular outcome programs; cagrilintide as a monotherapy is primarily supported by phase 2 evidence.
- The combination of the two (CagriSema, 2.4 mg + 2.4 mg) produced greater weight reduction in early trials than either compound alone, which is why the pair is often studied together rather than head-to-head.
Research Summary
Cagrilintide and semaglutide target two independent appetite-regulation systems: the amylin/calcitonin receptor family and the GLP-1 receptor. Both are lipidated peptides with roughly week-long half-lives suited to once-weekly protocols. Rather than direct competitors, they are best understood as complementary tools; combination research (CagriSema) explores whether engaging satiation and incretin pathways simultaneously produces additive metabolic effects.
What is the difference between cagrilintide and semaglutide?
Cagrilintide is a long-acting amylin analog that promotes satiation through amylin and calcitonin receptors in the hindbrain, while semaglutide is a GLP-1 receptor agonist acting on incretin pathways. Both have ~7-day half-lives. They engage independent systems, and combination research (CagriSema) studies whether using both simultaneously produces greater metabolic effects than either alone.
More Comparisons
Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.